Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 1.00 |
| ▸ | TLR4 | O00206 | 4/20 | 0.64 |
| ▸ | TLR2 | O60603 | 4/20 | 0.64 |
| ▸ | FBP1 | P09467 | 7/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437026 | 1.00 | VCP (1.00) | VCPTLR4TLR2FBP1CYP11B1 | |
| SCHEMBL30778142 | 1.00 | VCP (1.00) | VCPTLR4TLR2FBP1CYP11B1 | |
| SCHEMBL510245 | 0.78 | TLR4 (0.70) | VCPTLR4TLR2FBP1ALDH1A1 | |
| SCHEMBL510246 | 0.78 | TLR4 (0.70) | VCPTLR4TLR2FBP1ALDH1A1 | |
| SCHEMBL76743 | 0.77 | MAPT (0.67) | VCPFBP1CYP11B1CYP11B2MAPT | |
| SCHEMBL76742 | 0.77 | MAPT (0.67) | VCPFBP1CYP11B1CYP11B2MAPT | |
| SCHEMBL29691623 | 0.77 | CYP11B1 (0.86) | VCPCYP11B1CYP11B2MAPTKDM4E | |
| SCHEMBL29691639 | 0.77 | CYP11B1 (0.86) | VCPCYP11B1CYP11B2MAPTKDM4E | |
| SCHEMBL940946 | 0.76 | FBP1 (0.63) | VCPTLR4TLR2FBP1MAPT | |
| SCHEMBL940945 | 0.76 | FBP1 (0.63) | VCPTLR4TLR2FBP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534792-A | Super-hydrophobic intelligent response ion and electron conductive flexible electronic gel and preparation method and application thereof | 陕西科技大学 | 2024-02-09 | — | — | CN | claimed |
| EP-2982368-A1 | Small molecule compounds displacing focal adhesion core components | Universität Konstanz (DE) | 2016-02-10 | — | — | EP | claimed |
| CN-117534792-A | Super-hydrophobic intelligent response ion and electron conductive flexible electronic gel and preparation method and application thereof | 陕西科技大学 | 2024-02-09 | — | — | CN | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2982368-A1 | Small molecule compounds displacing focal adhesion core components | Universität Konstanz (DE) | 2016-02-10 | — | — | EP | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2852591-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| CN-101495480-A | Constrained compounds as cgrp-receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | disclosed |
| US-7560473-B2 | Amine derivative with potassium channel regulatory function, its preparation and use | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. (CN) | 2009-07-14 | — | — | US | disclosed |
| CN-101048406-A | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-10-03 | — | — | CN | disclosed |
| CN-1842526-A | Benzodiazepine CGRP receptor antagonists | MERCK & CO INC (US) | 2006-10-04 | — | — | CN | disclosed |
| US-20040266822-A1 | Amine derivative with potassium channel regulatory function, its preparation and use | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2004-12-30 | — | — | US | disclosed |
| EP-1386908-A1 | AMINE DERIVATIVE WITH POTASSIUM CHANNEL REGULATORY FUNCTION, ITS PREPARATION AND USE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2004-02-04 | — | — | EP | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | VCP 1236/4885TLR4 3303/4885TLR2 4146/4885 |
| US-20040266822-A1 | Amine derivative with potassium channel regulatory function, its preparation and use | KCNMA1, KCNA5, KCNA1 | VCP 1922/4885TLR4 1871/4885TLR2 2779/4885 |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | VCP 1236/4885TLR4 3303/4885TLR2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.